
Biotechnology investment firm that creates and funds therapeutics companies, including via its BioImpact arm

UK EIS and SEIS funds investing in early-stage biotech therapeutics and related AI

O2h Ventures manages funds for UK taxpayers who want exposure to young biotech and life-science companies through the Enterprise Investment Scheme (EIS) and the Seed Enterprise Investment Scheme (SEIS). It describes itself as turning UK biotech breakthroughs into impact, backing teams from seed stage through to clinical success. Every page opens with a plain risk warning: this is a high-risk investment, investors could lose everything they put in, and they are unlikely to be protected if something goes wrong.
This fund is described as Britain's first EIS knowledge intensive fund approved by HMRC. Its focus is the seeding of early-stage biotech therapeutics and related artificial intelligence opportunities. It invests in companies that qualify under EIS and that cover novel drug discovery, along with the services, tools and AI technologies that support it.
A companion fund looks at seed-stage companies under SEIS. Its scope matches the first fund, covering new approaches to drug discovery together with enabling services, tools and AI. The two vehicles let the firm work with a company at different points of its early life.
The newer Seven Sisters Human Health EIS Growth Fund turns to UK biotech companies at growth stage that are developing new therapeutics, drug discovery platforms and wider life-science innovation. Per the firm, a subscription is typically used to build a portfolio of between five and ten unquoted or AIM-listed companies. It aims to put capital to work within twelve months but says it will only invest when it finds suitably exciting opportunities, which may stretch that period.
The firm explains that capital comes back to investors only when it can sell the shares, usually after three to seven years. It will look to exit after three years so that the tax reliefs are not lost, though it may hold longer for a better result, or exit earlier even where reliefs could be forfeited.
O2h says its access to deals comes from grassroots working relationships in the biotech community. It also points to its own 2.7 acre Mill SciTech Park, from which the fund can incubate life-science companies. The firm argues that AI helps make sense of the large volumes of data involved in finding new therapeutics and in deciding where to spend research resources.
Investors must identify as a high net worth individual, a sophisticated investor, or an adviser acting for a professional investor, and must self-certify under the financial promotion rules before viewing offers. Those who fit none of the categories are told they are not eligible. The site stresses that investors should subscribe only if they can bear losing their entire investment.
O2h Ventures runs UK tax-advantaged funds that invest in biotech and life-science companies. Its funds use the EIS and SEIS tax schemes, so they suit UK taxpayers who qualify for those reliefs. The firm warns that investors could lose all of what they put in.
UK biotech and drug-discovery companies, and investors who are high net worth or sophisticated. Prospective investors must self-certify their status before viewing the offers.
Summary written by TrustList from the business's own published information, Nov 2026.
2 images - click to enlarge
Used it? Your experience helps other buyers decide.
Write a reviewNo questions yet. Be the first to ask about O2h Ventures.
Similar listings buyers compare against this one.

Biotechnology investment firm that creates and funds therapeutics companies, including via its BioImpact arm

Venture firm investing in deep tech founders who turn scientific discoveries into companies

Midwest venture capital firm investing in early-stage healthcare companies, from diagnostics to life science tools

Early-stage venture investor in science and technology startups across Europe, now branded Verve Ventures

Venture capital firm investing in early-stage life sciences companies, mainly in Europe and Israel

Singapore-headquartered global investment company with a portfolio spread across five sectors

Corporate venture arm of Johnson & Johnson investing in healthcare companies from seed stage onwards

Merck's corporate venture fund investing in early-stage preclinical therapeutics companies
Everything here links back to the same verified catalogue. Pick your next stop.